ミシガン州における多発性骨髄腫の臨床試験
ミシガン州内の拠点で、多発性骨髄腫に関する26件の研究が参加者を募集しています。
ミシガン州内の都市
- Detroit19件の研究
- Ann Arbor10件の研究
- Grand Rapids8件の研究
- Warren4件の研究
- Lansing4件の研究
- Waterford3件の研究
- Flint3件の研究
- Livonia3件の研究
- Saginaw3件の研究
公式研究テキスト（英語）
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- START Midwest /ID# 279035, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07409246A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Michigan Health System, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT04634552A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
- Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Barbara Ann Karmanos Cancer Institute, Detroit
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05201781TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Henry Ford Health Saint John Hospital, Detroit
- Genesys Hurley Cancer Institute, Flint
- 他7件
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06953960A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Henry Ford Health System, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06980480A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT05714839AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- 他36件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Ann Arbor
- Research Site, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07284758A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/08更新 · NCT05137054Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
被験者募集中第4相
18歳以上 · 全性別 · 2026/07/01更新 · NCT06057402Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- KCI at McLaren Greater Lansing, Lansing
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/26更新 · NCT06107738Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Joseph Mercy Hospital, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Saint Joseph Mercy Brighton, Brighton
- 他51件
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Henry Ford St. John Hospital, Grosse Pointe Woods
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06433947A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT05828511A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Ann Arbor
- GSK Investigational Site, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Karmanos Cancer Institute, Detroit
被験者募集中
18歳以上 · 全性別 · 2025/08/26更新 · NCT06908629ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。